Physician profile
Aaron Holtebeck
NPI 1760400147
$14,789.26
in general payments reported to CMS, 2019-2025
29 companies · $1,264 in 2025
The $1,264 reported for 2025 was more than what 82% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,898 · 2020: $2,749 · 2021: $788 · 2022: $1,115 · 2023: $2,469 · 2024: $1,506 · 2025: $1,264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,122 · Consulting Fee: $1,100 · Education: $17.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,121.65 |
| Consulting Fee | $1,100.00 |
| Education | $17.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $7,963.18 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Alcon Vision LLC | $2,415.11 | 2019-2025 | Clareon, Argos, Clareon Panoptix Pro |
| Abbvie INC. | $2,136.31 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $303.46 | 2022-2024 | Eylea Hd, Eylea |
| Amgen INC. | $292.19 | 2024-2025 | Tepezza, Tavneos |
| Allergan, INC. | $229.12 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $170.86 | 2023-2025 | Syfovre |
| Astellas Pharma US INC | $126.17 | 2023 | Izervay |
| Glaukos Corporation | $118.16 | 2023-2024 | Idose, Photrexa |
| Mallinckrodt Hospital Products INC. | $115.46 | 2024-2025 | Acthar |
| Rayner Intraocular Lenses Limited | $106.97 | 2022-2023 | Rayone Aspheric, Omidria, Rayone Emv |
| New World Medical,INC. | $96.57 | 2023-2024 | Clearpath, Streamline, Kahook Dual Blade |
| Horizon Therapeutics Plc | $92.91 | 2022-2023 | Tepezza |
| Oyster Point Pharma, INC. | $79.07 | 2024 | Ryzumvi, Tyrvaya |
| Novartis Pharmaceuticals Corporation | $79.00 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $65.39 | 2023-2024 | Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Biotissue Holdings INC. | $48.84 | 2022-2025 | |
| Genentech USA, INC. | $48.35 | 2023 | Vabysmo |
| Tarsus Pharmaceuticals, INC. | $45.07 | 2024 | Xdemvy |
| Dompe US, INC. | $38.58 | 2025 | Oxervate |
| Thea Pharma INC. | $38.12 | 2023-2024 | Iyuzeh |
| Ocular Therapeutix, INC. | $32.70 | 2023 | Dextenza |
| Harrow Eye, LLC | $28.79 | 2024 | Vevye |
| Lkc Technologies, INC. | $28.59 | 2025 | |
| Bausch & Lomb Americas INC. | $25.83 | 2022-2024 | Miebo, Xiidra |
| Johnson & Johnson Surgical Vision, INC. | $25.52 | 2024 | Tecnis Iol |
| Lumibird Medical INC. | $14.00 | 2021 | |
| Shire North American Group INC | $13.63 | 2019 | |
| Omeros Corporation | $11.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Holtebeck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.